Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ZAVESCA

Summary for Tradename: ZAVESCA

Suppliers: see list1
patent expirations by year for

Pharmacology for Tradename: ZAVESCA

Clinical Trials for: ZAVESCA

A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction
Status: Not yet recruiting Condition: Pompe Disease; Hypersensitivity Reaction

Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis
Status: Active, not recruiting Condition: Gangliosidoses GM2

Miglustat in Niemann-Pick Type C Disease
Status: Completed Condition: Niemann-Pick Type C Disease

Miglustat / OGT 918 in the Treatment of Cystic Fibrosis
Status: Terminated Condition: Cystic Fibrosis

Two Period / Two Treatment Cross-over to Assess the Effect of Florastor® on Gastrointestinal Tolerability, Safety, and PK in Healthy Subjects Receiving Zavesca®
Status: Active, not recruiting Condition: Diarrhea

Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses
Status: Completed Condition: GM2 Gangliosidoses; Tay-Sachs; Sandhoff Disease

Application of Miglustat in Patients With Niemann-Pick Type C
Status: Completed Condition: Niemann-Pick Disease Type C

Oral Miglustat in Adult Patients With Stable Type 1 Gaucher Disease
Status: Completed Condition: Type 1 Gaucher Disease

Synergistic Enteral Regimen for Treatment of the Gangliosidoses
Status: Recruiting Condition: GM1 Gangliosidoses; GM2 Gangliosidoses; Tay-Sachs Disease; Sandhoff Disease

Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients ?
Status: Completed Condition: Cystic Fibrosis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion Pharms Ltd
CAPSULE;ORAL021348Jul 31, 2003RXYes<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology